Zhichao Shi

Zhichao Shi

Auto-generated profile, based on publicly available information

Zhichao Shi

Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen, 518132, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
WHWenjun Huang
Wenjun Huang
QZQingyun Zhu
Qingyun Zhu
ZSZhichao Shi
Zhichao Shi
YTYao Tu
Yao Tu
QLQinyuan Li
Qinyuan Li
YJYuyang Jiang
Yuyang Jiang
The existing conventional treatments for breast cancer, including immune checkpoint blockade, exhibit limited effects in some cancers, particularly triple-negative breast cancer. Epigenetic alterations, specifically DNMT and HDAC alterations, are implicated in breast cancer pathogenesis. We demonstrated that DNMTs and HDACs are overexpressed and positively correlated in breast cancer. The combination of DNMT and HDAC inhibitors has shown synergistic antitumour effects, and our previously designed dual DNMT and HDAC inhibitor (termed DNMT/HDACi) 15a potently inhibits breast cancer cell proliferation, migration, and invasion and induces apoptosis in vitro and in vivo. Mechanistically, 15a induces a viral mimicry response by promoting the expression of endogenous retroviral elements in breast cancer cells, thus increasing the intracellular level of double-stranded RNA to activate the RIG-I–MAVS pathway. This in turn promotes the production of interferons and chemokines and augments the expression of interferon-stimulated genes and PD-L1. The combination of 15a and an anti-PD-L1 antibody had an additive effect in vivo. These findings indicate that this DNMT/HDACi has immunomodulatory functions and enhances the effectiveness of immune checkpoint blockade therapy.

25 February 2021 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
ZSZhichao Shi
Zhichao Shi
TFTingting Fan
Tingting Fan
XZXun Zhang
Xun Zhang
FZFeng Zhan
Feng Zhan
ZWZhe Wang
Zhe Wang
YJYuyang Jiang
Yuyang Jiang

1 September 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
LTLin Tang
Lin Tang
WWWeibin Wu
Weibin Wu
CZCunlong Zhang
Cunlong Zhang
ZSZhichao Shi
Zhichao Shi
DCDawei Chen
Dawei Chen
YJYuyang Jiang
Yuyang Jiang

7 February 2026 in Environmental Research
Verified
Journal Article
Closed access
QZQi Zeng
Qi Zeng
ZSZhichao Shi
Zhichao Shi
SDShijing Deng
Shijing Deng
TWTingbiao Wu
Tingbiao Wu
LWLihong Wu
Lihong Wu
QLQinglian Li
Qinglian Li

22 August 2024 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ZWZuoyang Wang
Zuoyang Wang
ZSZhichao Shi
Zhichao Shi
SYShiqi Yang
Shiqi Yang
ZNZizhou Niu
Zizhou Niu
KSKaifei Shu
Kaifei Shu
YJYuyang Jiang
Yuyang Jiang

20 June 2025 in Organic Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
ZSZhichao Shi
Zhichao Shi
TFTingting Fan
Tingting Fan
JLJin-Shun Lin
Jin-Shun Lin
WXWeibin Xie
Weibin Xie
FZFeng Zhan
Feng Zhan
YJYuyang Jiang
Yuyang Jiang
Chiral oxazolidines are pivotal structural motifs commonly found in natural products, medicinally important compounds, and chiral ligands. Among various synthetic strategies, the asymmetric formal (3 + 2) annulation of donor–acceptor (D–A) aziridines with dipolarophiles has emerged as a powerful method for constructing enantioenriched five-membered azaheterocycles with potential bioactivity. Herein, we present a Cu(II)/chiral phosphoric acid (CPA) cooperative catalytic system for the asymmetric intermolecular (3 + 2) cycloaddition of D–A aziridines with aldehydes via C–C bond cleavage. This approach enables the efficient and highly enantioselective synthesis of cis-(2S,5S)-1,3-oxazolidines with excellent atom economy, as well as exceptional chemo-, enantio-, and diastereoselectivities. This novel activation model, distinct from existing catalytic methodologies, serves as a complementary approach that significantly broadens the scope of asymmetric (3 + 2) cycloaddition of D–A aziridines. Moreover, the resulting chiral oxazolidines exhibited significant anti-proliferative activity against various human cancer cell lines, highlighting their potential for further advancement in medicinal chemistry.